Sangamo Therapeutics, Inc. (0R1D.L)
USD 0.82
(5.75%)
USD 0.82
(5.75%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -257.83 Million USD | -34.09% |
| 2022 | -192.27 Million USD | -7.84% |
| 2021 | -178.29 Million USD | -47.2% |
| 2020 | -121.12 Million USD | -59.75% |
| 2019 | -75.81 Million USD | -10.95% |
| 2018 | -68.33 Million USD | -25.23% |
| 2017 | -54.56 Million USD | 23.85% |
| 2016 | -71.65 Million USD | -76.05% |
| 2015 | -40.7 Million USD | -54.08% |
| 2014 | -26.41 Million USD | 0.78% |
| 2013 | -26.62 Million USD | -19.58% |
| 2012 | -22.26 Million USD | 37.72% |
| 2011 | -35.75 Million USD | -43.84% |
| 2010 | -24.85 Million USD | -33.72% |
| 2009 | -18.58 Million USD | 23.52% |
| 2008 | -24.3 Million USD | -13.14% |
| 2007 | -21.48 Million USD | -20.24% |
| 2006 | -17.86 Million USD | -34.39% |
| 2005 | -13.29 Million USD | 3.8% |
| 2004 | -13.81 Million USD | -32.45% |
| 2003 | -10.43 Million USD | 64.95% |
| 2002 | -29.76 Million USD | -17.88% |
| 2001 | -25.24 Million USD | -178.5% |
| 2000 | -9.06 Million USD | -138.58% |
| 1999 | -3.8 Million USD | -15.68% |
| 1998 | -3.28 Million USD | -134.64% |
| 1997 | -1.4 Million USD | -354.55% |
| 1996 | -308 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -36.12 Million USD | 26.4% |
| 2024 Q1 | -49.08 Million USD | 18.59% |
| 2023 FY | -257.83 Million USD | -34.09% |
| 2023 Q2 | -114.5 Million USD | -641.84% |
| 2023 Q3 | -104.16 Million USD | 9.03% |
| 2023 Q4 | -60.29 Million USD | 42.11% |
| 2023 Q1 | 21.13 Million USD | 140.66% |
| 2022 Q3 | -53.15 Million USD | -23.12% |
| 2022 FY | -192.27 Million USD | -7.84% |
| 2022 Q1 | -43.97 Million USD | -17.28% |
| 2022 Q2 | -43.17 Million USD | 1.83% |
| 2022 Q4 | -51.97 Million USD | 2.22% |
| 2021 Q2 | -47.16 Million USD | -2.69% |
| 2021 Q1 | -45.93 Million USD | -13.12% |
| 2021 Q4 | -37.49 Million USD | 21.37% |
| 2021 Q3 | -47.68 Million USD | -1.1% |
| 2021 FY | -178.29 Million USD | -47.2% |
| 2020 Q2 | -35.92 Million USD | 16.27% |
| 2020 Q1 | -42.91 Million USD | -1042.11% |
| 2020 Q4 | -40.6 Million USD | -2519.61% |
| 2020 Q3 | -1.55 Million USD | 95.69% |
| 2020 FY | -121.12 Million USD | -59.75% |
| 2019 Q2 | -30.28 Million USD | 28.15% |
| 2019 Q4 | 4.55 Million USD | 116.68% |
| 2019 Q3 | -27.3 Million USD | 9.83% |
| 2019 FY | -75.81 Million USD | -10.95% |
| 2019 Q1 | -42.15 Million USD | -125.84% |
| 2018 Q2 | -16.64 Million USD | 17.57% |
| 2018 Q4 | -18.66 Million USD | -45.32% |
| 2018 FY | -68.33 Million USD | -25.23% |
| 2018 Q1 | -20.18 Million USD | -54.21% |
| 2018 Q3 | -12.84 Million USD | 22.82% |
| 2017 Q1 | -16.63 Million USD | -72.82% |
| 2017 Q2 | -12.49 Million USD | 24.9% |
| 2017 Q3 | -12.35 Million USD | 1.1% |
| 2017 Q4 | -13.09 Million USD | -5.97% |
| 2017 FY | -54.56 Million USD | 23.85% |
| 2016 Q3 | -18.96 Million USD | 28.64% |
| 2016 Q1 | -16.49 Million USD | -17.7% |
| 2016 FY | -71.65 Million USD | -76.05% |
| 2016 Q2 | -26.57 Million USD | -61.12% |
| 2016 Q4 | -9.62 Million USD | 49.25% |
| 2015 Q1 | -5.31 Million USD | -23.15% |
| 2015 Q2 | -12.12 Million USD | -127.98% |
| 2015 FY | -40.7 Million USD | -54.08% |
| 2015 Q3 | -9.24 Million USD | 23.76% |
| 2015 Q4 | -14.01 Million USD | -51.57% |
| 2014 Q2 | -6.98 Million USD | 7.81% |
| 2014 FY | -26.41 Million USD | 0.78% |
| 2014 Q3 | -7.54 Million USD | -8.08% |
| 2014 Q4 | -4.31 Million USD | 42.76% |
| 2014 Q1 | -7.57 Million USD | 7.02% |
| 2013 Q1 | -6.88 Million USD | -97.96% |
| 2013 Q3 | -6.14 Million USD | -12.75% |
| 2013 Q4 | -8.14 Million USD | -32.53% |
| 2013 FY | -26.62 Million USD | -19.58% |
| 2013 Q2 | -5.45 Million USD | 20.84% |
| 2012 Q1 | -7.26 Million USD | -14.29% |
| 2012 Q2 | -5.72 Million USD | 21.19% |
| 2012 Q3 | -5.79 Million USD | -1.08% |
| 2012 Q4 | -3.47 Million USD | 39.93% |
| 2012 FY | -22.26 Million USD | 37.72% |
| 2011 Q1 | -9.57 Million USD | -15.11% |
| 2011 Q2 | -10.25 Million USD | -7.11% |
| 2011 Q3 | -9.55 Million USD | 6.87% |
| 2011 Q4 | -6.35 Million USD | 33.44% |
| 2011 FY | -35.75 Million USD | -43.84% |
| 2010 Q4 | -8.32 Million USD | 4.3% |
| 2010 Q1 | -3.97 Million USD | -66.23% |
| 2010 FY | -24.85 Million USD | -33.72% |
| 2010 Q2 | -3.86 Million USD | 2.97% |
| 2010 Q3 | -8.69 Million USD | -125.26% |
| 2009 Q4 | -2.39 Million USD | 50.67% |
| 2009 Q2 | -4.51 Million USD | 33.97% |
| 2009 Q1 | -6.83 Million USD | -165.42% |
| 2009 Q3 | -4.85 Million USD | -7.54% |
| 2009 FY | -18.58 Million USD | 23.52% |
| 2008 Q2 | -7.41 Million USD | 6.94% |
| 2008 FY | -24.3 Million USD | -13.14% |
| 2008 Q4 | -2.57 Million USD | 59.4% |
| 2008 Q3 | -6.34 Million USD | 14.54% |
| 2008 Q1 | -7.97 Million USD | -19.48% |
| 2007 Q3 | -4.26 Million USD | 17.62% |
| 2007 Q2 | -5.18 Million USD | 3.32% |
| 2007 Q1 | -5.35 Million USD | 40.11% |
| 2007 Q4 | -6.67 Million USD | -56.33% |
| 2007 FY | -21.48 Million USD | -20.24% |
| 2006 FY | -17.86 Million USD | -34.39% |
| 2006 Q3 | -2.84 Million USD | 14.49% |
| 2006 Q2 | -3.32 Million USD | -21.25% |
| 2006 Q1 | -2.74 Million USD | -1.89% |
| 2006 Q4 | -8.94 Million USD | -214.52% |
| 2005 Q3 | -3.66 Million USD | -8.49% |
| 2005 Q2 | -3.38 Million USD | 4.87% |
| 2005 Q1 | -3.55 Million USD | -16.76% |
| 2005 FY | -13.29 Million USD | 3.8% |
| 2005 Q4 | -2.69 Million USD | 26.56% |
| 2004 FY | -13.81 Million USD | -32.45% |
| 2004 Q1 | -2.94 Million USD | -75.12% |
| 2004 Q2 | -3.26 Million USD | -10.88% |
| 2004 Q3 | -4.57 Million USD | -40.13% |
| 2004 Q4 | -3.04 Million USD | 33.43% |
| 2003 FY | -10.43 Million USD | 64.95% |
| 2003 Q1 | -2.89 Million USD | -310.06% |
| 2003 Q4 | -1.68 Million USD | 34.98% |
| 2003 Q3 | -2.58 Million USD | 21.08% |
| 2003 Q2 | -3.27 Million USD | -13.09% |
| 2002 Q4 | -706 Thousand USD | 96.63% |
| 2002 FY | -29.76 Million USD | -17.88% |
| 2002 Q3 | -20.94 Million USD | -476.7% |
| 2002 Q2 | -3.63 Million USD | 19.08% |
| 2002 Q1 | -4.48 Million USD | -33.3% |
| 2001 Q1 | -2.06 Million USD | 26.49% |
| 2001 FY | -25.24 Million USD | -178.5% |
| 2001 Q4 | -3.36 Million USD | 80.66% |
| 2001 Q3 | -17.4 Million USD | -621.09% |
| 2001 Q2 | -2.41 Million USD | -17.07% |
| 2000 Q2 | -1.72 Million USD | 36.53% |
| 2000 Q1 | -2.71 Million USD | 0.0% |
| 2000 FY | -9.06 Million USD | -138.58% |
| 2000 Q4 | -2.8 Million USD | -54.29% |
| 2000 Q3 | -1.81 Million USD | -5.39% |
| 1999 FY | -3.8 Million USD | -15.68% |
| 1998 FY | -3.28 Million USD | -134.64% |
| 1997 FY | -1.4 Million USD | -354.55% |
| 1996 FY | -308 Thousand USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Imunon, Inc. | -19.51 Million USD | -1221.196% |
| Homology Medicines, Inc. | -53.74 Million USD | -379.748% |
| uniQure N.V. | -308.47 Million USD | 16.418% |
| Abeona Therapeutics Inc. | -54.18 Million USD | -375.808% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | -191.397% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 26.771% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | -70.091% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 6.626% |
| bluebird bio, Inc. | -211.91 Million USD | -21.668% |
| Blueprint Medicines Corporation | -506.98 Million USD | 49.144% |
| Cara Therapeutics, Inc. | -118.51 Million USD | -117.555% |
| Adicet Bio, Inc. | -142.65 Million USD | -80.734% |
| Dynavax Technologies Corporation | -6.38 Million USD | -3935.545% |
| Editas Medicine, Inc. | -153.21 Million USD | -68.276% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | -23.218% |
| Geron Corporation | -184.12 Million USD | -40.029% |
| Heron Therapeutics, Inc. | -110.55 Million USD | -133.207% |
| Illumina, Inc. | -1.16 Billion USD | 77.792% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 41.935% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 118.986% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 132.687% |
| Myriad Genetics, Inc. | -112 Million USD | -130.206% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 203.256% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 51.895% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 19692.021% |
| Verastem, Inc. | -87.36 Million USD | -195.113% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 97.014% |
| Waters Corporation | 642.23 Million USD | 140.146% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 107.123% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 104.301% |
| Biogen Inc. | 1.16 Billion USD | 122.206% |
| Nektar Therapeutics | -276.05 Million USD | 6.602% |
| Viking Therapeutics, Inc. | -85.89 Million USD | -200.17% |
| Perrigo Company plc | -12.7 Million USD | -1930.165% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -546.841% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -478.053% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 253.796% |
| Evolus, Inc. | -61.68 Million USD | -317.98% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 106.521% |
| FibroGen, Inc. | -284.23 Million USD | 9.289% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 120.793% |
| OPKO Health, Inc. | -188.86 Million USD | -36.517% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 41.434% |
| Exelixis, Inc. | 207.76 Million USD | 224.097% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -442.745% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 46.418% |
| Zoetis Inc. | 2.34 Billion USD | 111.0% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | -7.772% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -510.988% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 29.609% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 342.916% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 191.561% |
| Insmed Incorporated | -749.56 Million USD | 65.603% |
| TG Therapeutics, Inc. | 12.67 Million USD | 2134.651% |
| Incyte Corporation | 597.59 Million USD | 143.144% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 66.097% |